Stereotaxis, Inc.

Stereotaxis is a pioneer in endovascular robotics and robotic-assisted interventional medicine. The company develops and commercializes robotic systems designed to enhance precision and control in minimally invasive cardiovascular and other interventional procedures. Their primary focus is cardiac ablation therapy, where robotic-assisted navigation enables physicians to perform complex catheter-based treatments with improved safety and efficacy. The company markets solutions to interventional cardiologists, electrophysiologists, and hospital systems, positioning robotic assistance as an alternative to traditional manual catheterization. Stereotaxis operates a B2B model directed at hospital networks and interventional centers, with clinical data and peer-reviewed evidence supporting their technology. The company also offers telemedicine-enabled robotic capabilities (TeleRobotics), expanding procedural access geographically. Products are marketed through direct sales to hospitals and physician networks, with clinical training and support provided to end users.